Mandated Coverage for Certain COVID-19 Antibody Therapies

On March 22, 2021, Commissioner Birrane invoked her emergency powers to require health insurance carriers to provide coverage for monoclonal antibody therapies. This includes Bamlanivimab and the combination of Casirivimab and Imdevimab. Any cost sharing, including copayments, coinsurance and deductibles must be waived.

Although this mandated coverage applies to health insurance carriers, employer plan sponsors should be aware of this change.

Bulletin 21-09 »